SEC Is Investing Illumina Over Its Acquisition of Cancer Test Developer Grail

The U.S. Securities and Exchange Commission is investigating Illumina over its controversial $7.1 billion acquisition of cancer test developer Grail, the DNA sequencing company said in a securities filing late Thursday.

Last month, the SEC informed Illumina about the probe and requested documents and communications related to the deal. The agency also asked for statements and disclosures about the “conduct and compensation” of certain members of both Illumina and Grail’s management, according to the filing.

Illumina, in the filing, said it is cooperating with the SEC. An agency spokesperson did not immediately respond to CNBC’s request for comment on the investigation.

Read the source article at CNBC